Acute Lymphoblastic Leukemia Clinical Trial
Official title:
A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Verified date | May 2021 |
Source | Chongqing Precision Biotech Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in patients with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.
Status | Completed |
Enrollment | 9 |
Est. completion date | September 1, 2021 |
Est. primary completion date | June 29, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 21 Years |
Eligibility | Inclusion Criteria: 1. Diagnosed with B-ALL,and meet one of the following conditions: 1. First-line or multiple-line salvage chemotherapy did not achieve complete remission; 2. Early relapse after complete remission (<12 months), or late relapse after complete remission (=12 months) and complete remission has not been achieved after 1 course of treatment; 3. Relapse after autologous or allogeneic hematopoietic stem cell transplantation; 2. Ph+ALL patients should also receive at least two TKI treatments; 3. For allogeneic hematopoietic stem cell transplant subjects, the following conditions must be met: 1. Allo-HSCT takes =6 months before pCAR-19B infusion; 2. No GVHD of grade 2 or above occurred within 2 weeks before PBMC collection; 4. Express CD19; 5. 3~21 years old, no gender limit; 6. The expected survival time is more than 12 weeks; 7. KPS>60; 8. No serious mental disorders; 9. The function of important organs is basically normal: 1. Heart function: echocardiography indicates that the cardiac ejection fraction is =50%, and the electrocardiogram has no obvious abnormalities; 2. Renal function: serum creatinine=2.0×ULN; 3. Liver function: ALT and AST =5×ULN; 4. Total bilirubin and alkaline phosphatase=3×ULN ; 5. Blood oxygen saturation>92%. 10. Have standards for apheresis or venous blood collection, and no other cell collection contraindications; 11. The patient himself or his guardian agrees to participate in the clinical trial and signs the ICF, indicating that he understands the purpose and procedures of the clinical trial and is willing to participate in the research. Exclusion Criteria: 1. With central nervous system disease at the time of screening; 2. Have received CAR-T therapy or other genetically modified cell therapy; 3. Participated in other clinical studies within 1 month before screening; 4. Have received the following anti-tumor treatments before screening: received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter); 5. Have received a live attenuated vaccine within 4 weeks before screening; 6. Cerebrovascular accident or seizure occurred within 6 months before signing the ICF; 7. Suffered from any of the following heart diseases: 1. NYHA stage III or IV congestive heart failure; 2. Myocardial infarction or CABG occurred =6 months before enrollment; 3. Clinically significant ventricular arrhythmia, or history of unexplained syncope (except for cases caused by vasovagal or dehydration); 4. History of severe non-ischemic cardiomyopathy. 8. Uncontrollable infection in the 2 weeks before screening; 9. Active autoimmune diseases; 10. Patients with malignant tumors other than acute lymphoblastic leukemia within 5 years before screening, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and duct in situ after radical resection cancer; 11. HBsAg or HBcAb positive and HBV DNA is greater than the normal range; HCV antibody is positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis positive; CMV DNA positive; 12. Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving pCAR-19B cell reinfusion; 13. Other situations considered by the researcher to be unsuitable to participate in the study. |
Country | Name | City | State |
---|---|---|---|
China | Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Chongqing Precision Biotech Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Adverse events after pCAR-19B infusion [Safety and Tolerability] | Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) | 28 days | |
Primary | Obtain the maximum tolerated dose of pCAR-19B cells[Safety and Tolerability] | Dose-limiting toxicity after cell infusion | 28 days | |
Secondary | Objective response rate after pCAR-19B infusion [Effectiveness] | Objective response rate includes CR, CRi | 3 months | |
Secondary | AUCS of pCAR-19B cells [Cell dynamics] | AUCS is defined as the area under the curve in 28 days and 90 days | 3 months | |
Secondary | CMAX of pCAR-19B cells [Cell dynamics] | CMAX is defined as the highest concentration of pCAR-19B cells expanded in peripheral blood | 3 months | |
Secondary | TMAX of pCAR-19B cells [Cell dynamics] | TMAX is defined as the time to reach the highest concentration | 3 months | |
Secondary | Pharmacodynamics of pCAR-19B cells[Cell dynamics] | Cytokines such as hs-CRP, IL-6 levels | 3 months | |
Secondary | Immunogenicity of pCAR-19B cells | Anti-CAR antibody | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |